Specialty pharmacy PANTHERx Rare Pharmacy announced on Tuesday that it has been chosen by California-based BridgeBio to distribute Attruby (acoramidis), a high-affinity transthyretin (TTR) stabiliser for twice daily oral administration.

Attruby is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). It is the first and only approved product with a label specifying near-complete stabilisation of TTR.

Attruby was designed to mimic a naturally occurring 'rescue mutation' of the TTR gene (T119M) that targets the root cause of ATTR-CM, destabilisation of the native TTR tetramer. Through near-complete TTR stabilisation, Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes.

Rob Snyder, PANTHERx Rare Pharmacy executive chair, said: "Panther is committed to providing tailored solutions for people living with rare and devastating conditions and we look forward to the partnership with BridgeBio and serving the needs of patients suffering from transthyretin amyloid cardiomyopathy."